Immix Biopharma shareholders elect directors and ratify Crowe LLP as auditor at 2026 annual meeting

Immix Biopharma, Inc.

All nine director nominees (including Ilya Rachman, Gabriel Morris, Jason Hsu) elected with over 35M votes each; broker non-votes ~6.4M.
Ratification of Crowe LLP as independent auditor for FY 2026 passed: 42.3M For, 11.5K Against, 18.4K Abstentions.
Meeting held May 22, 2026; results reported on May 29, 2026; overwhelming support for all proposals.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immix Biopharma, Inc. shareholders approved Ratification of Auditors at the 2026-05-22 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-22

Exact text from the filing

The stockholders ratified the appointment of Crowe LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of the voting for this proposal were as follows: For Against Abstentions Broker Non-Votes 42,276,496 11,526 18,442 —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Immix Biopharma, Inc. shareholders approved Election of Directors at the 2026-05-22 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-22

Exact text from the filing

The stockholders elected each of the individuals listed below to serve as a director of the Company until the next annual meeting of stockholders and until such director’s successor is duly elected and qualified. The results of the voting for this proposal were as follows: For Withheld Broker Non-Votes Ilya Rachman 35,738,887 121,893 6,445,684 Gabriel Morris 34,353,302 1,507,479 6,445,683 Jason Hsu 35,844,812 15,969 6,445,683 Magda Marquet 35,731,188 129,592 6,445,684 Helen C. Adams 35,677,258 183,522 6,445,684 Carey Ng 35,840,860 19,921 6,445,683 Jane Buchan 35,731,346 129,434 6,445,684 Yekaterina Chudnovsky 35,749,420 111,360 6,445,684 Nancy Chang 35,744,455 116,325 6,445,684

View on SEC.gov

Browse all shareholder votes →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-026431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.